Almirall Patent-Cliff Exposure & CMS Drug Spending Portfolio

Almirall (US): 6 reconciled FDA prescription therapies (0.2% 2025 to 2030 cliff risk), $9.2M 2024 CMS Part D & Medicaid spend, and $1,556 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies6
2025 to 2030 Patent-Cliff Revenue Exposure0.2%
Primary Portfolio LOE Date2027-01-01
2024 CMS Total Public Spend$9.2M
2024 Medicare Part D Spend$9.2M
2024 Medicaid Spend$0
California HCAI SB 17 FilingsSpecialty launch notice ($1,556 intro WAC)